We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

134 hedge funds and large institutions have $101M invested in Emergent Biosolutions in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.74% more ownership

Funds ownership: 79.49% → 81.22% (+1.7%)

5% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 44

15% less call options, than puts

Call options by funds: $443K | Put options by funds: $520K

17% less funds holding

Funds holding: 162 → 134 (-28)

28% less capital invested

Capital invested by funds: $141M → $101M (-$39.7M)

59% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 46

Holders
134
Holders Change
-28
Holders Change %
-17.28%
% of All Funds
1.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
46
Reduced
44
Closed
46
Calls
$443K
Puts
$520K
Net Calls
-$77K
Net Calls Change
+$189K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$4.37M
2
Charles Schwab
Charles Schwab
California
+$3.09M
3
BlackRock
BlackRock
New York
+$2.26M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$1.53M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.46M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$3.69M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.65M
3
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management
California
-$1.84M
4
Squarepoint
Squarepoint
New York
-$1.19M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$936K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$22.6M +$2.26M +963,517 +11%
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.14M +$771K +328,272 +12%
Charles Schwab
3
Charles Schwab
California
$6.9M +$3.09M +1,312,934 +84%
Morgan Stanley
4
Morgan Stanley
New York
$5.93M +$4.37M +1,860,672 +305%
Millennium Management
5
Millennium Management
New York
$5.03M -$3.69M -1,570,717 -43%
Hotchkis & Wiley Capital Management
6
Hotchkis & Wiley Capital Management
California
$3.95M -$1.84M -781,247 -32%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$2.85M +$588K +250,034 +27%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.63M +$184K +78,184 +8%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$2.61M +$47.9K +20,400 +2%
State Street
10
State Street
Massachusetts
$2.55M -$162K -69,004 -6%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$2.5M -$476K -202,736 -16%
Two Sigma Investments
12
Two Sigma Investments
New York
$2.49M +$6.17K +2,624 +0.3%
PGCM
13
Prescott Group Capital Management
Oklahoma
$2.05M +$1.3M +554,162 +185%
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$2M +$1.53M +651,480 +356%
Goldman Sachs
15
Goldman Sachs
New York
$1.8M +$219K +93,301 +14%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$1.58M -$337K -143,383 -18%
Qube Research & Technologies (QRT)
17
Qube Research & Technologies (QRT)
United Kingdom
$1.49M +$1.46M +621,177 New
BCM
18
Bridgeway Capital Management
Texas
$1.48M -$593K -252,148 -29%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.31M +$1.29M +547,300 New
AQR Capital Management
20
AQR Capital Management
Connecticut
$1.23M +$786K +334,298 +187%
CSS
21
Cubist Systematic Strategies
Connecticut
$1.21M +$384K +163,545 +48%
Allspring Global Investments
22
Allspring Global Investments
North Carolina
$1.1M +$15.8K +6,724 +1%
Northern Trust
23
Northern Trust
Illinois
$1.08M -$86.6K -36,871 -8%
PCM
24
Palisade Capital Management
New Jersey
$1.08M -$138K -58,913 -12%
Ameriprise
25
Ameriprise
Minnesota
$1.03M -$31.7K -13,495 -3%
1
2 3 4 5

EBS Hedge Fund Activity: Q4 2023 in Review

134 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2023, worth a combined $101M — down 28% from $141M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of EBS and 19 opened new positions — a net loss of 27 holders — while 44 trimmed existing stakes and 46 added.

The largest buyer was Morgan Stanley, adding an estimated $4.37M. The largest seller was Millennium Management, cutting an estimated $3.69M.

  • 134 institutional investors held Emergent Biosolutions (EBS) as of Q4 2023, down from 162 in Q3 2023.
  • Funds reported $101M of Emergent Biosolutions stock for Q4 2023, down 28% quarter-over-quarter.
  • 19 funds opened new Emergent Biosolutions positions in Q4 2023 and 46 closed out, a net change of -27 holders.
  • The largest Emergent Biosolutions buyer in Q4 2023 was Morgan Stanley, an estimated $4.37M added.
  • The largest Emergent Biosolutions seller in Q4 2023 was Millennium Management, an estimated $3.69M sold.

Based on aggregated 13F filings for Q4 2023.